BNET Industries
- Private
- CA
Dow Jones Description
Only 30 minutes from the heart of downtown Vancouver, the University of British Columbia holds an international reputation for excellence in advanced research and learning. The spectacular UBC campus is a 'must-see' for any visitor to the city -- where snow-capped mountains meet ocean, and breathtaking vistas greet you around every corner. The university boasts some of the city's best attractions & recreation facilities, including the Museum of Anthropology, the Chan Centre for the Performing Arts, the UBC Botanical Garden and Centre for Plant Research, and endless opportunities to explore forested trails in the adjoining 763-hectare Pacific Spirit Regional Park.
Contact Information
2329 West Mall
Vancouver, British Columbia V6T 1Z4
604.822.2211
NAICS Code Colleges, Universities, and Professional Schools: 611310
News & Analysis
Filter by
healthcare and technology and university of british columbia - All News and Analysis
EnWave Corporation: Vaccine, Drug Process Patents Filed.
- 2007-02-22
VANCOUVER, BRITISH COLUMBIA, Feb 22, 2007 CCNMatthews via COMTEX -- EnWave Corporation (TSX VENTURE:ENW) (the "Company") wishes to report that Dr. Tim Durance, in conjunction with other researchers at the University of British Columbia UBC, has filed US CIP and international PCT patent applications to protect...
MIV Therapeutics Highlights 2005 Scientific and Strategic Milestones in Development of New Generation Biomedical Technologies; Year-End Report Cites Achievements in Breakthrough Drug Delivery and Other Solutions for Multi-Billion-Dollar Markets
- 2006-01-04
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, has reported significant progress in a report outlining the achievement of numerous key strategic, corporate and technological objectives for 2005. "The past year has been a time of...
MIV Therapeutics' Passive Stent Coatings Accepted for Presentation at Prestigious World Conference on Cardiovascular Therapy; Interim Results of Animal Trials of Proprietary HAp Coating to be Detailed at TCT 2005 Conference
- 2005-09-12
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced that interim results of a long-term animal study of its proprietary ultra-thin Hydroxyapatite coating will be featured at this year's 17th annual Transcatheter Cardiovascular...
MIV Therapeutics Reports Scientific and Business Achievements in Corporate Review for First Six Months of 2005; Milestones Position Company as Leading Innovator of Next-Generation Biocompatible Coronary Stents and Drug-Delivery Technologies
- 2005-07-08
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies for the treatment of cardiovascular disease, has reported significant progress in a report outlining the achievement of numerous key corporate and technological objectives for the first half of 2005. MIVT has...
MIVT LICENSES BIOCOMPATIBLE MEDICAL DEVICE COATINGS.
- 2005-07-01
MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has exercised the option provided in the collaborative research agreement with The University of British Columbia UBC to license two new technologies for advanced biocompatible coatings for cardiovascular stents and...
MIV Therapeutics Exercises Option to License Additional Proprietary Technologies for Biocompatible Drug-Eluting Coatings; New Licenses from U. of British Columbia will Strengthen Intellectual Property Portfolio in Novel Coatings for Medical Devices
- 2005-06-08
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced it has exercised the option provided in its Collaborative Research Agreement with the University of British Columbia UBC to license two additional technologies for advanced biocompatible and drug-eluting coatings for...
MIV Therapeutics Expands Intellectual Property Portfolio with New Technologies for Next-Generation Biocompatible Medical Device Coatings
- 2005-05-20
VANCOUVER, British Columbia -- Proprietary Technologies, Licensed from Univ. of British Columbia, Include New Coatings for Advanced Drug-Eluting Applications MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced that it has exercised the Option provided in the Collaborative Research Agreement with The...
MIV Therapeutics Announces 2004 Year-End Review: Milestones Achieved in Development of Revolutionary Coatings for Medical Devices; Technology Increases Body's Acceptance of Implanted Devices, Provides Advanced Therapeutic Functionality
- 2005-03-15
VANCOUVER, British Columbia -- MIV Therapeutics Inc. (OTCBB:MIVT), a developer of next-generation drug-eluting coatings that inhibit the rejection of implanted medical devices, has announced the Company's successful achievement of all key milestones planned in its 2004 research and development program. The Company is progressing toward commercialization of a revolutionary new...
- 1
Glass Door
| Company | Employer Rating |
| Alcoa |  |
| CBS Corp |  |
| Johnson & Johnson | |
| Costco Wholesale |  |
|
IndustryTop Rated
